Actavis has announced that G. Frederick Wilkinson, President, Actavis Global R&D, will leave the company effective April 25, 2014.  The company noted that Mr. Wilkinson has accepted the position of President and Chief Executive Officer at Impax Laboratories, Inc.

"Over the past five years, Fred has played an essential role in our evolution from a primarily generics company to a leading specialty pharmaceutical company," said Paul M. Bisaro, Chairman and CEO of Actavis.  "He was instrumental in the successful launch of Rapaflo and Gelnique, revitalized the brand oral contraceptive category with the innovative launch of Generess Fe, and has broadly expanded the nascent brand development pipeline he inherited in 2009 both org

anically and through M&A activities.  He was also instrumental in establishing our biosimilar strategy, which today includes five products in development, including four under the Amgen/Actavis collaboration.
"Throughout our evolution to brand leadership, he has played a critical role in the acquisitions of Uteron Pharma SA, which enhanced our product pipeline; as well as the Warner Chilcott plc acquisition last year and the proposed acquisition of Forest Laboratories, Inc.

Although we regret his departure, Fred's colleagues and I recognize the substantial opportunity that has been presented to him, and we wish him continued success in his new role.  It is with great respect that I note that Fred's counsel will be missed." Mr. Wilkinson was appointed President, Global R&D on January of 2014.

He joined then Watson as Executive Vice President, Global Brands in September 2009 and was appointed President of Global Specialty Brands in January, 2013.

Actavis Global R&D will report to Robert Stewart, President, Actavis Global Operations.